Oktober 2026
Erstellen Sie ein Konto, um Similarweb weiterhin zu nutzen
Lassen sie sich Website-Metriken, Keywords, Top-Marketing-Kanäle, Marktforschungs-Tools und mehr anzeigen.
Erstellen Sie Ihr kostenloses Kontoscholar.google.com.pr
Globaler Rang
- -
Länderranking
- -
Kategorischer Rang
- -
Geschätzte Daten von Similarweb anzeigen.
Überprüfen Sie die Metriken Ihrer Website öffentlich, indem Sie Ihr GA4 verbinden
Reflektieren Sie Ihren Erfolg
Überprüfen Sie die Traffic- und Engagement-Metriken Ihrer Website durch Verbinden mit Google Analytics
Absprungrate
75.55%
Verweildauer
1.89
Durchschnittliche Besuchsdauer
00:00:36
- Unternehmen
- - -
- Branche
- - -
Top 10 scholar.google.com.pr Wettbewerber
Die Top-10-Websites wie scholar.google.com.pr in Oktober 2026 sind in absteigender Reihenfolge nach ihrer Affinität zu scholar.google.com.pr in Bezug auf den jeweiligen Schlüsselwörter-Traffic, das Zielgruppen-Targeting und entsprechende Marktüberschneidungen aufgeführt
sciencedirect is the world's leading source for scientific, technical, and medical research. explore journals, books and articles.
- Unternehmen
- ScienceDirect
Globaler Rang
#369
10Absprungrate
31.28%
Verweildauer
6.01
Durchschnittliche Besuchsdauer
00:07:55
Similarity-Score
100%Explore options for your family: the YouTube Kids app or a parent supervised account for older kids & teens on YouTube, all with built-in protections.
- Unternehmen
- YouTube
Globaler Rang
#2
Absprungrate
23.61%
Verweildauer
11.07
Durchschnittliche Besuchsdauer
00:18:45
Similarity-Score
86%academia.edu is a place to share and follow research.
- Unternehmen
- Academia
Globaler Rang
#1,547
31Absprungrate
61.51%
Verweildauer
2.35
Durchschnittliche Besuchsdauer
00:01:41
Similarity-Score
80%Access 160+ million publication pages and connect with 25+ million researchers. Join for free and gain visibility by uploading your research.
Globaler Rang
#407
7Absprungrate
46.91%
Verweildauer
3.59
Durchschnittliche Besuchsdauer
00:03:06
Similarity-Score
76%We perform a behavioral experiment of karma, a class of mechanisms for repeated resource allocation with attractive fairness and efficiency properties, in theory. Individuals in these mechanisms bid non-tradable credits that flow from resource consumers to yielders. Human subjects recruited on Amazon MTurk are repeatedly and randomly paired to bid karma according to time-varying individual urgency to acquire resources. Treatments varied in the urgency process (frequent moderate versus sporadic high urgency) and the richness of the bidding scheme (binary versus full range). Benchmarked against random allocation, karma achieves an (almost) Pareto improvement, despite subjects deviating from the theoretically optimal Nash bidding policy: maximum improvement is attained by subjects deviating by up to one karma bid unit on average, and positive improvement with deviations of up to 3-4 units. These findings hold across all treatments, among which no significant differences are found, with the exception of the sporadic high urgency process with binary bidding being (weakly) favorable. They offer behaviorally robust lower bounds for karma's expected performance in human populations and guide its future implementation.
- Unternehmen
- - -
- Branche
- - -
Globaler Rang
#1,994
145Absprungrate
39.23%
Verweildauer
3.17
Durchschnittliche Besuchsdauer
00:04:08
Similarity-Score
73%indexingmethod_automated - Search Results - PubMed
- Unternehmen
- - -
- Branche
- - -
Globaler Rang
- -
Länderranking
- -
Kategorischer Rang
- -
Absprungrate
- -
Verweildauer
- -
Durchschnittliche Besuchsdauer
- -
Similarity-Score
71%the world’s largest collection of open access research papers
- Unternehmen
- - -
- Branche
- - -
Globaler Rang
#36,852
20,099Absprungrate
26.98%
Verweildauer
5.13
Durchschnittliche Besuchsdauer
00:04:27
Similarity-Score
65%Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 mont
- Unternehmen
- - -
- Branche
- - -
Globaler Rang
#74,009
9,111Absprungrate
24.78%
Verweildauer
3.71
Durchschnittliche Besuchsdauer
00:01:07
Similarity-Score
62%Learn more about our institutional models for librarians and the benefits for researchers.
- Unternehmen
- PLOS
Globaler Rang
#17,323
1,917Absprungrate
61.54%
Verweildauer
1.75
Durchschnittliche Besuchsdauer
00:01:42
Similarity-Score
61%DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
- Unternehmen
- - -
- Branche
- - -
Globaler Rang
#26,873
5,777Absprungrate
19.35%
Verweildauer
4.43
Durchschnittliche Besuchsdauer
00:01:51
Similarity-Score
59%scholar.google.com.prDie Top-5-Wettbewerber in Oktober 2026 lauten: sciencedirect.com, youtube.com, academia.edu, researchgate.net und mehr.
Laut Similarweb-Daten zu monatlichen Besuchen ist sciencedirect.com in Oktober 2026 der Top-Wettbewerber von scholar.google.com.pr. Die zweitähnlichste Website ist youtube.com, gefolgt von academia.edu auf Platz 3.
researchgate.net ist die viertähnlichste Website zu scholar.google.com.pr, während arxiv.org in Oktober 2026 den fünften Platz belegt.
Die weiteren fünf Wettbewerber in der Top-10-Liste sind pubmed.ncbi.nlm.nih.gov, core.ac.uk, scienceopen.com, plos.org und doaj.org.